Use of timed alarm device for pediatric daytime urinary incontinence: Meta-analysis of comparative studies

Michael Chua1,2,3, Mandy Rickard2, Jin Kyu Kim4, Natasha Brownrigg2, Joana Dos Santos2, Luzelle Kate Aba3, Armando Lorenzo2, Niraj Mistry5
1 Global Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada; 2Division of Urology, Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada; 3Institute of Urology, St. Luke's Medical Center, Quezon City, NCR, Philippines; 4Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 5Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada


Published online December 6, 2022

Corresponding author: Dr. Michael Chua, Division of Urology, Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada; michael.chua@sickkids.ca

***

ABSTRACT

Introduction: This meta-analysis aimed to determine the comparative effectiveness of timed alarm device-assisted urotherapy vs. standard urotherapy alone in managing pediatric daytime urinary incontinence (pDUI).

Methods: A systematic literature search was performed in December 2021, with an update search in July 2022. Comparative studies assessing the pDUI treatment effectiveness of timed alarm device-assisted urotherapy vs. urotherapy alone were identified and evaluated according to Cochrane collaboration recommendations. The assessed outcome includes pDUI complete response and adherence rates. Relative risk (RR) with 95% confidence intervals (CI) was extrapolated. A random-effects model was used to pool effect estimates. Heterogeneity was assessed with sensitivity and subgroup analysis performed according to study design and comparative group characteristics. GRADE criteria were used to assess evidence certainty. PROSPERO (CRD42022299173).

Results: Four studies (three randomized controlled trials [RCTs] and one retrospective cohort) with 635 cases were included. The pooled effect estimates of pDUI complete response showed no differences between intervention groups (RR 1.20, 95% CI 0.81, 1.76). Pooled effect estimates for treatment adherence were generated from two studies, which showed significantly
better adherence for the timed-alarm device group (RR 2.97, 95% CI 1.46, 6.06). Significant interstudy heterogeneity was noted; the source is likely from the study design and comparator device characteristics. The quality of evidence was assessed to be of very low certainty. **Conclusions:** Based on very low certainty evidence, timed alarm device-assisted urotherapy does not seem to have the advantage of complete treatment response over standard urotherapy alone in managing pDUI; however, a timed-alarm device is likely able to improve urotherapy treatment adherence.

**INTRODUCTION**

According to the International Children’s Continence Society (ICCS), daytime urinary incontinence (DUI) is defined as intermittent involuntary urine leakage during the daytime wake period among children ages five years old or older (1). A recent ICCS standardization document for the treatment of DUI recommends that treatment modalities be tailored according to the individual child's condition (2). Given that the majority (>65%) of the DUI etiology in children is determined to be functional (3); hence, urotherapy is considered the primary intervention after organic and concomitant medical morbidities have been ruled out (2). Specifically, according to some studies, behavioral modification (timed voiding, avoidance of urine holding, and optimizing voiding posture) treated 40-45% of DUI in children (4, 5).

Timed alarm devices such as alarm watches are being suggested to enhance pediatric DUI treatment (2, 6). Notably, the suggested mechanism of action for the timed alarm device is timed voiding reminders of school-age children (7). Prior studies have shown the superiority of urotherapy with a timed alarm device over standard urotherapy alone (8, 9); however, a recent study has shown no difference in treatment outcomes (10). Due to inconsistent reported evidence, this systematic review and meta-analysis aimed to determine the comparative effectiveness of timed alarm device-assisted urotherapy versus standard urotherapy alone in managing DUI among children.

**METHODS**

The meta-analysis protocol was made in consultation with a topic expert and review methodologist, subsequently registered priori at the PROSPERO registry CRD42022299173. The meta-analysis was conducted according to the Cochrane Collaboration recommendation and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (11, 12).

**Identification and evaluation of the literature**

A comprehensive literature search with no language restriction was carried out initially in December 2021, then an update search in July 2022 to identify published medical literature of
human studies on the use of any timed alarm device in the management of pediatric daytime urinary incontinence. The databases used were MEDLINE, EMBASE, Scopus, and PubMed, while Google Scholar and Clinicaltrial.gov were searched for grey literature and trial registry for unpublished data. The platform/database-specific search strategies are detailed in Appendix A. In addition, relevant Cochrane reviews and studies that met our inclusion criteria were cross-referenced for potentially eligible records.

This meta-analysis included comparative studies, such as randomized controlled trials (RCTs, prospective and retrospective cohorts) that compare clinical outcomes of the use of timed alarm device-assisted urotherapy versus standard urotherapy alone or with other non-timed devices in the management of pediatric DUI. Excluded studies were non-comparative trials, reviews, commentaries, non-assessment of clinical outcome response rate, and adult population studies. The primary outcome considered in this meta-analysis was the post-intervention response rate, specifically complete response, which according to ICCS defined as a 100% reduction in wet days per week (1, 2). The secondary outcome assessed was treatment adherence, defined by the individual studies.

The retrieved records from the databases were imported into systematic review software-Covidence App (13). Once duplicate records were removed, unique records were independently evaluated by two of the three reviewers (MR, NM & MEC). Records that either reviewer flagged were retrieved for full-text and were further determined whether they met the inclusion criteria. The full-text review was performed independently by another two reviewers (MEC and NB) who were knowledgeable in the principles of critical appraisal. The risk of bias, quality of the design, execution, and data analysis of studies were assessed according to Cochrane Collaborative recommendations using ROBs for RCTs and ROBINS-I for non-RCT comparative studies (14, 15). Differences in the assessment were resolved through consensus.

Data extraction, synthesis, and measures of treatment effect

One reviewer extracted and summarized the study characteristics and outcome assessment of the included studies and counter-verified by another (LKA). The RevMan5 program from www.Cochrane.org was used to report the data outcome extracted from the studies (16). Dichotomous data of the treatment response rate per intervention group were extrapolated as risk ratios (RR) with 95% confidence intervals (95% CI). Effect estimates were pooled using the Inverse Variance (IV) method with the random effects model. The random-effects model meta-analyses were chosen to provide a more conservative estimate by considering both the estimates of between-study variation (i.e., study heterogeneity) and the small study sample size (12, 17). Intention to treat analysis was applied to each study, with all drop-outs considered non-responders and non-treatment adherents. When reported by the studies, adverse events were summarized with detailed descriptive analysis.
Assessment of heterogeneity, subgroup analysis, publication bias, and GRADE criteria
The Chi² statistical test for heterogeneity and the overlap of confidence intervals on the forest plot assessed the heterogeneity between different studies. A p-value of 0.10 was used to show heterogeneity, and the I² statistic of >40% was used to identify substantial between studies variations (12). The source of heterogeneity among the study characteristics was then determined by considering the clinical and methodological characteristics of the included studies. Subgroup analysis was performed according to the study design and comparator device. A funnel plot was generated to assess the possibility of publication bias. Finally, the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria was used to assess the certainty of the synthesized evidence from the meta-analysis (18).

RESULTS
The initial literature search from December 2021 retrieved 106 records. An update search on July 2022 retrieved 292 from the same databases, PubMed, and additional 200 records screened from Googlescholar and registered trials from clinicaltrials.gov. From the total of 398 records, 114 duplicates were removed, and 284 records were screened for relevance. Subsequently, 268 records were excluded based on the relevance of the studies. The full-text article was retrieved for the 16 studies. Upon full-text review, 12 studies were excluded based on various reasons detailed in Figure 1.

Characteristics of the included studies
Four studies (3 RCTs and 1 retrospective cohort) with 635 cases (timed alarm device = 232, control/comparator = 403) were included for the meta-analysis (8-10, 19). Two studies were from Denmark (8, 9), one from the UK (19), and one from Australia (10). One study compared the timed alarm device (watch) assisted urotherapy to a control group of standard urotherapy with a similar watch device but was not set for a specific time (10). One study compared another device that set the alarm when urine contacted the sensor in the diaper (19), while two other studies used a timer watch and compared it to standard urotherapy alone (8, 9). All enrolled patients ranged from 5 to 15 years old in the included studies. The follow-up period ranges from 3 to 24 months; most studies have a three-month treatment assessment. All studies reported the treatment response as complete dryness, and two studies further adapted the ICCS definition of response and partial response (8, 10). Treatment adherence was assessed by the same two studies (8, 10). Table 1 details the included studies’ detailed characteristics.

Treatment effect
The pooled effect estimates of complete response showed no between-group differences (RR=1.20, 95%CI 0.81, 1.76). Subgroup analysis was performed according to the study design. Pooled effect estimates from RCTs showed no between-group difference (RR=1.27, 95%CI 0.59, 2.71) Figure 2A; subgroup analysis considering only the studies compared with standard urotherapy also showed no between-group differences (RR=1.40, 95%CI 0.92, 2.12) Figure 2B. Among the
RCTs, there was noted significant inter-study heterogeneity. However, when the subgroup performed according to comparative group characteristics, inter-study heterogeneity was not significant—Source of heterogeneity was likely from the study design and comparator device characteristics as a confounder.

Pooled effect estimates for treatment adherence were generated from two studies, which showed significantly better for the timed alarm device compared to the comparator group (RR=2.97, 95%CI 1.46, 6.06) Figure 3. Inter-study heterogeneity was borderline significant; when the analysis was performed according to per-protocol analysis without assuming a lost to follow-up patients as non-adherent, the heterogeneity became insignificant (Supplementary Figure A).

Among the included studies, only one reported the safety concern of using timed alarm devices, which was described as tolerable to the families and had no reported significant adverse effects (10).

**Study quality, risk of bias, publication bias, and GRADE criteria**

Based on the risk of bias 2 tool, the included RCTs were assessed as having some concerns and to high risk of bias (Table 2). Most of the concerns for risk of bias were due to no detailed information on the randomization process and allocation. While for the Non-RCT retrospective study included was assessed according to ROBINS-I as having serious to critical risk of bias, which was due to bias from confounder and selection of participants to the intervention and departure from the intended intervention.

Publication bias based on the generated funnel plot showed a likelihood of a small study effect. (Supplementary Figure B). Specifically, the small sample-sized RCT gave significantly higher effect estimates for the timed alarm device. Based on GRADE criteria, some to high concerns of risk of bias, significant heterogeneity, and the possibility of publication bias have downgraded the evidence as very low certainty (18).

**DISCUSSION**

Standard urotherapy is recommended as the first-line management of pediatric DUI (2). Furthermore, timed voiding is an integral part of standard urotherapy that aim at reducing urinary incontinence by preventing over-flow incontinence and improving bladder control as behavioral modification among toilet-trained children (2). Although, in the management of adult DUI, timed voiding was assessed to be effective with an 80% complete response rate (20); however, despite that majority of the DUI in children were functional and non-organic, this was reported to be less effective in pediatric DUI, (2, 5).

Using a timed alarm device as a regular reminder for timed voiding is postulated to increase compliance among pediatric DUI to behavioral modification of standard urotherapy (2, 8). This meta-analysis finding has supported such postulation, which showed approximately
three times improved treatment adherence among patients with timed alarm devices compared to standard urotherapy alone.

However, despite the improved treatment adherence, there was no significant difference in the pooled effect estimates for the overall complete response rate between the treatment groups. While standard urotherapy is highly effective in treating functional pDUI; however, as suggested by the ICCS position statement on pDUI, when refractory to standard urotherapy, pDUI patients need further adjunctive pharmacological management and need to be evaluated for neurogenic or anatomic etiology (2). Another plausible explanation for the noted equivocal complete response rate between the two-intervention groups could be due to the placebo effect of the control device. Among the included studies that utilized comparative devices, Cadwell et al. (2022) and Halliday et al. (1987) (10, 19), their control groups had better overall complete response rates compared to the literature that used only standard urotherapy alone without placebo/another device as control (5, 8).

Despite the effort of performing a sensitive search strategy and extensive search for evidence, the inherent limitation of this systematic review and meta-analysis is the limited amount of available comparative studies that assess the differential effectiveness of timed alarm devices versus standard urotherapy alone. Although randomized controlled trials were included, the methodological quality of these studies was assessed to be of some concern for risk of bias. Moreover, a significant inter-study variability and the possibility of publication bias were noted, which further limited the certainty of the generated evidence. Based on the GRADE criteria, the evidence from available literature was determined to be very low to generate recommendations (18). However, from a clinical perspective, with the recognized low to no adverse effect of the timed alarm device (10), clinicians may consider adding a timed alarm device to standard urotherapy among pediatric DUI identified as refractory due to poor compliance. Furthermore, future studies may consider identifying the pediatric DUI subgroup that could benefit from adding a timed alarm device.

CONCLUSIONS
Based on the available very low certainty evidence, timed alarm device-assisted urotherapy does not seem to have the advantage of complete treatment response over standard urotherapy alone in managing pediatric DUI. However, a timed alarm device was determined to be likely to improve treatment adherence to timed voiding. Therefore, future studies may consider identifying a pediatric DUI subgroup that may render a complete DUI treatment response for timed alarm devices.
References


© 2022 Canadian Urological Association
Figures and Tables

**Figure 1.** PRISMA 2020 flow diagram for systematic reviews, which included searches of databases and registers only. Adapted from Page MJ, et al. *BMJ* 2021;372:n71. For more information, visit: http://www.prisma-statement.org/.
Figure 2A. Forest plot pooled effect estimates for outcome of complete response rate (CRR); comparison: timed alarm vs. control/other device; subgroup: study design (RCTs and non-RCTs). Statistical method: Inverse variance with random-effect model (relative risk [RR] and 95% confidence interval [CI]). RCT: randomized controlled study.

Figure 2B. Forest plot pooled effect estimates for outcome of complete response rate (CRR); comparison: timed alarm vs. control/other device; subgroup: study design (control and other device). Statistical method: Inverse variance with random-effect model (relative risk [RR] and 95% confidence interval [CI]).
Figure 3. Forest plot pooled effect estimates for outcome of treatment adherence; comparison: timed alarm vs. control; subgroup: none. Statistical method: Inverse variance with random-effect model (relative risk [RR] and 95% confidence interval [CI]).
### Table 1. Detailed study characteristics of included studies

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Country</th>
<th>Study method</th>
<th>Population</th>
<th>Intervention description</th>
<th>Comparison description</th>
<th>Outcome comparison</th>
<th>Followup duration</th>
<th>Timed alarm</th>
<th>Comparator</th>
<th>Outcome (success)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halliday (1987)</td>
<td>U.K.</td>
<td>RCT</td>
<td>Children aged 5–15 attend children's incontinence clinic. Mean age 8.5 (SD 2.1) years (ranges 5–13). 35 girls. Daytime wetting since infancy in 34. They were associated with enuresis in 20 and fecal soiling in 5</td>
<td>Flat plastic wetting sensor alarm (Headingley Scientific Instruments, Leeds) does not go off with a buzzer when urine is in contact with the sensor; instead, the set alarm buzzes almost every 2 hours</td>
<td>Flat plastic wetting sensor alarm (Headingley Scientific Instruments, Leeds) goes off with a buzzer when urine is in contact with the sensor</td>
<td>Success rate is defined as 6 consecutive weeks without daytime wetting</td>
<td>Treatment up to 3 months, followup within one month after stopping treatment.</td>
<td>22/19 (2 drop out)</td>
<td>22/20 (2 drop out)</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>Hagstroem (2008)</td>
<td>Denmark</td>
<td>Retrospective cohort</td>
<td>All children were treated for daytime urinary incontinence from 2000–2004 at the Center for Child incontinence clinic. All children received prior urotherapy for at least 1 month and were resistant</td>
<td>Standard urotherapy with timer watch</td>
<td>Standard urotherapy alone</td>
<td>The response is defined as a complete daytime continent for 14 days</td>
<td>Followed at least 24 months</td>
<td>60</td>
<td>230</td>
<td>42</td>
<td>126</td>
</tr>
<tr>
<td>Hagstroem (2010)</td>
<td>Denmark</td>
<td>RCT</td>
<td>Children referred to Center for Child Incontinence, 5–14 years at least 1 episode of daytime incontinence weekly, voiding</td>
<td>Timer assisted-watch with 7 alarms (Triax, Nike Inc., Oregon)</td>
<td>Standard urotherapy alone, daily fluid intake at least 1200 ml per day, timed voiding</td>
<td>Response defined as ICCS of full response of complete</td>
<td>Followup for 12 weeks for assessment of</td>
<td>30</td>
<td>28</td>
<td>9</td>
<td>0</td>
</tr>
</tbody>
</table>
**CUAJ – Review**

**Chua et al**

Timed alarms for pediatric daytime urinary incontinence

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study Design</th>
<th>Participant Details</th>
<th>Interventions</th>
<th>Urotherapy Similar to Control Group</th>
<th>Personalized Alarm Watch to Vibrate at Approximately 2-hr Intervals During the Day and Locked to Prevent Tampering</th>
<th>Response by 3 Months, Complete Response Defined as 100% Reduction</th>
<th>Followup at 3 Months</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caldwell (2021)</td>
<td>Australia</td>
<td>RCT</td>
<td>Children aged 5–13 years with daytime urinary incontinence at least 2x/week for at least 2 weeks before enrollment and referred to urinary incontinence service at a Children’s Hospital. Previously prescribed timed voiding as part of urotherapy and continued with other treatments, including</td>
<td>Urotherapy similar to control group and personalized alarm watch to vibrate at approximately 2-hr intervals during the day and locked to prevent tampering</td>
<td>Identical watch to intervention group but does not vibrate and encourage to void regularly approx 2-hr intervals. Urotherapy - regular voiding education, adequate hydration, avoidance of caffeinated drinks, healthy diet, management of constipation</td>
<td>Followup at 3 months</td>
<td>120/116</td>
<td>123/110</td>
<td>Only 100% complete response was included for meta-analysis. Reported no side effect from treatment alarm watch 61/66, control 62/66 (p=0.7)</td>
</tr>
</tbody>
</table>

© 2022 Canadian Urological Association
### Timed alarms for pediatric daytime urinary incontinence

| **anticholinergic medications,** treatment of constipation, behavioral therapy, and psychologic support |

---

**IVP:** intravenous pyelogram. **KUB:** kidney-ureter-bladder. **RCT:** randomized controlled trial. **SD:** standard deviation. **VCUG:** voiding cystourethrogram.
Table 2. Study quality assessment according to risk of bias tool

<table>
<thead>
<tr>
<th>ROBINS-I</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Overall bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author (year)</td>
<td>Study design</td>
<td>Bias due to confounding</td>
<td>Bias in selection of participants into the study</td>
<td>Bias in measurement of interventions</td>
<td>Bias due to departures from intended interventions</td>
<td>Bias due to missing data</td>
<td>Bias in measurement of outcomes</td>
<td>Bias in selection of the reported result</td>
</tr>
<tr>
<td>Halliday (1987)</td>
<td>RCT</td>
<td></td>
<td></td>
<td>Low</td>
<td>Serious</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hagstroem (2008)</td>
<td>Retrospective cohort</td>
<td>Serious</td>
<td>Serious</td>
<td>Low</td>
<td>Serious</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hagstroem (2010)</td>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caldwell (2021)</td>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| ROB-RCT                         |          |          |          |          |          |          |          | Overall bias |
| Author (year)                   | Study design | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Other potential bias | Overall bias |
| Halliday (1987)                 | RCT      | Some concern | Low concern | Low concern | Low concern | Low concern | Low concern | Some concern |
| Hagstroem (2008)                | Retrospective cohort | Some concern | Some concern | Low concern | Some concern | Low concern | Some concern | Some concern |
| Hagstroem (2010)                | RCT      | Some concern | Some concern | Low concern | Some concern | Low concern | Some concern | Some concern |
| Caldwell (2021)                 | RCT      | Low concern | Low concern | Some concern | Low concern | Low concern | Some concern | Some concern |

RCT: randomized controlled trial.